Dr. M, who knows more than all of us put together, says the cash situation is fine and Anavex has enough for 2 years (LPC might still be used to ensure this fact).
that $20M is insufficient self funding for the proposals AVXL has voiced.
So obvious. Anyone who has been in biotech for any longer than a week and reads prs on Friday AH knows how much cash companies need to raise for clinical trials. Twenty million? Most serious investors would see this as a red flag.